Pharmather eyes commercialization of Parkinson’s ketamine treatment
Pharmather is advancing its ketamine-based treatment for Parkinson’s disease as the approval decision date of Aug. 9, 2025, set by the U.S. Food and Drug Administration (FDA) draws closer. If approved, the company plans to market the product under the brand name Ketarx and expand its use in neurological conditions,…